| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S10096-013-1944-3 |
| P953 | full work available at URL | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3892112 |
| P932 | PMC publication ID | 3892112 |
| P698 | PubMed publication ID | 24026863 |
| P5875 | ResearchGate publication ID | 256501643 |
| P2093 | author name string | R Barnes | |
| S Haider | |||
| C Charbonneau | |||
| J Stephens | |||
| A Khachatryan | |||
| L Drgona | |||
| M Kantecki | |||
| P2860 | cites work | Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis | Q28217179 |
| Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America | Q28263689 | ||
| Azole cross-resistance in Aspergillus fumigatus | Q28345187 | ||
| Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis | Q33301106 | ||
| The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients | Q33718895 | ||
| Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006 | Q33723583 | ||
| Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study | Q33800526 | ||
| One year prospective survey of Candida bloodstream infections in Scotland. | Q33910250 | ||
| Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience | Q34455699 | ||
| Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. | Q34680777 | ||
| Candida guilliermondii fungemia in patients with hematologic malignancies | Q34719843 | ||
| Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. | Q34936576 | ||
| Invasive pulmonary aspergillosis: identification of risk factors | Q35063631 | ||
| Newer combination antifungal therapies for invasive aspergillosis. | Q35642204 | ||
| A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK. | Q35987403 | ||
| Prevention and treatment of cancer-related infections | Q37101802 | ||
| Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/ | Q37164067 | ||
| Candida parapsilosis infection in very low birthweight infants. | Q37174924 | ||
| Therapeutic outcome and prognostic factors of invasive aspergillosis in an infectious disease department: a review of 34 cases. | Q37326430 | ||
| Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. | Q37344532 | ||
| Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update | Q37421528 | ||
| Candidaemia in an Irish tertiary referral hospital: epidemiology and prognostic factors. | Q50763957 | ||
| Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study--Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. | Q51184875 | ||
| Invasive Aspergillosis as an Opportunistic Infection in Nonallografted Patients with Multiple Myeloma: A European Organization for Research and Treatment of Cancer | Q56837355 | ||
| Epidemiology of invasive aspergillosis in France: a six-year multicentric survey in the Greater Paris area | Q56941303 | ||
| Reduction of Invasive Aspergillosis Incidence among Immunocompromised Patients after Control of Environmental Exposure | Q57208477 | ||
| Early Mannan Detection in Bronchoalveolar Lavage Fluid With Preemptive Treatment Reduces the Incidence of Invasive Candida Infections in Preterm Infants | Q59294830 | ||
| Galactomannan Does Not Precede Major Signs on a Pulmonary Computerized Tomographic Scan Suggestive of Invasive Aspergillosis in Patients with Hematological Malignancies | Q59308866 | ||
| Risk factors for invasive fungal infection in neonates | Q77935362 | ||
| Invasive aspergillosis: is treatment with "inexpensive" amphotericin B cost saving if "expensive" voriconazole is only used on demand? | Q79331475 | ||
| Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Spain | Q79786886 | ||
| A retrospective nationwide case study on the use of a new antifungal agent: patients treated with caspofungin during 2001-2004 in Finland | Q80015663 | ||
| Invasive aspergillosis in critically ill patients without malignancy | Q80269940 | ||
| Invasive fungal infections in autologous stem cell transplant recipients: a nation-wide study of 1188 transplanted patients | Q80405699 | ||
| Changing pattern of candidaemia 2001-2006 and use of antifungal therapy at the University Hospital of Vienna, Austria | Q80858945 | ||
| Hospital-wide prospective mandatory surveillance of invasive aspergillosis in a French teaching hospital (2000-2002) | Q81417212 | ||
| Seasonality of invasive Candida infection in neonates | Q81695952 | ||
| Increasing incidence of invasive aspergillosis in pediatric hematology oncology patients over the last decade: a retrospective single centre study. | Q37580698 | ||
| Systematic review and mixed treatment comparison of randomized evidence for empirical, pre-emptive and directed treatment strategies for invasive mould disease | Q37823013 | ||
| ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients | Q37934487 | ||
| ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. | Q38058556 | ||
| Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital | Q38899448 | ||
| Risk factors for fluconazole-resistant candidemia | Q39934814 | ||
| Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers | Q40346459 | ||
| Clinically driven diagnostic antifungal approach in neutropenic patients: a prospective feasibility study | Q40376327 | ||
| High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia. | Q40380606 | ||
| Empirical antifungal therapy in selected patients with persistent febrile neutropenia. | Q40387020 | ||
| Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. | Q40395042 | ||
| An early CT-diagnosis-based treatment strategy for invasive fungal infection in allogeneic transplant recipients using caspofungin first line: an effective strategy with low mortality | Q40399765 | ||
| Clinical impact of enhanced diagnosis of invasive fungal disease in high-risk haematology and stem cell transplant patients | Q40401499 | ||
| Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study | Q40497134 | ||
| Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. | Q40524039 | ||
| Invasive Aspergillosis in Italian AIDS patients | Q40569326 | ||
| Workload due to Aspergillus fumigatus and significance of the organism in the microbiology laboratory of a general hospital. | Q41791143 | ||
| Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands | Q43470906 | ||
| Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach. | Q43501661 | ||
| Cost-effectiveness analysis of micafungin versus caspofungin for treatment of systemic Candida infections in the UK. | Q43722644 | ||
| Liposomal amphotericin B (AmBisome): efficacy and safety of low-dose therapy in pulmonary fungal infections | Q43860670 | ||
| Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome | Q44457591 | ||
| Candidosis and aspergillosis as autopsy findings from 1994 to 2003. | Q44883914 | ||
| A multicentre pharmacoepidemiological study of therapeutic practices in invasive fungal infections in France during 1998-1999. | Q44962026 | ||
| Standards of care for patients with invasive fungal infections within the United Kingdom: a national audit | Q45014381 | ||
| Neonatal candidiasis: analysis of epidemiology, drug susceptibility, and molecular typing of causative isolates | Q45191154 | ||
| Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). | Q46072663 | ||
| A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT. | Q46200207 | ||
| Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study. | Q46260028 | ||
| Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients | Q46286203 | ||
| Voriconazole treatment of invasive aspergillosis: real-world versus health-economic model results | Q46504408 | ||
| Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany. | Q46597980 | ||
| Beta-D-glucan detection test: a step toward preemptive therapy for fungal infections in leukemic patients? | Q46764168 | ||
| Economic evaluation of voriconazole in the treatment of invasive aspergillosis in the Netherlands | Q46765392 | ||
| Trends in the postmortem epidemiology of invasive fungal infections at a university hospital | Q46828427 | ||
| Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany. | Q46915139 | ||
| Invasive aspergillosis in critically ill patients: analysis of risk factors for acquisition and mortality | Q49124894 | ||
| P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | aspergillosis | Q259626 |
| candidiasis | Q273510 | ||
| disease burden | Q5282120 | ||
| P1104 | number of pages | 15 | |
| P304 | page(s) | 7-21 | |
| P577 | publication date | 2013-09-12 | |
| 2014-01-01 | |||
| P1433 | published in | European Journal of Clinical Microbiology & Infectious Diseases | Q15754378 |
| P1476 | title | Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillus and Candida species | |
| P478 | volume | 33 |
| Q64241491 | A CRISPR Interference Platform for Efficient Genetic Repression in |
| Q48215394 | A Comparison of Aspergillus and Mucorales PCR Testing of Different Bronchoalveolar Lavage Fluid Fractions from Patients with Suspected Invasive Pulmonary Fungal Disease |
| Q61449824 | A Fungal World: Could the Gut Mycobiome Be Involved in Neurological Disease? |
| Q92235446 | Basic principles of the virulence of Cryptococcus |
| Q31162323 | Burden and treatment patterns of invasive fungal infections in hospitalized patients in the Middle East: real-world data from Saudi Arabia and Lebanon |
| Q47667654 | Characterization of carboxylate nanoparticle adhesion with the fungal pathogen Candida albicans |
| Q98161956 | Comparative performance evaluation of Wako β-glucan test and Fungitell assay for the diagnosis of invasive fungal diseases |
| Q52575674 | De-escalation of antifungal treatment in critically ill patients with suspected invasive Candida infection: incidence, associated factors, and safety. |
| Q38658275 | Development of antifungal therapies using nanomaterials |
| Q40562962 | Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant. |
| Q58784319 | Effectiveness and Tolerability of Micafungin in Chinese Patients with Invasive Fungal Infections: A Retrospective, Multicenter Study |
| Q53704443 | Elevated MIC Values of Imidazole Drugs against Aspergillus fumigatus Isolates with TR34/L98H/S297T/F495I Mutation. |
| Q64948530 | Epidemiology and Clinical Features of Invasive Fungal Infection in a US Health Care Network. |
| Q92632552 | Essential Oils of Lamiaceae Family Plants as Antifungals |
| Q89885707 | Hope on the Horizon: Novel Fungal Treatments in Development |
| Q64084323 | Identification of Off-Patent Compounds That Present Antifungal Activity Against the Emerging Fungal Pathogen |
| Q40213570 | Involvement of brain cytokines in zymosan-induced febrile response |
| Q34474946 | Isavuconazole: A New Option for the Management of Invasive Fungal Infections |
| Q26778187 | Meta-Analysis and Cost Comparison of Empirical versus Pre-Emptive Antifungal Strategies in Hematologic Malignancy Patients with High-Risk Febrile Neutropenia |
| Q52309400 | Multilocus Sequence Typing Reveals a New Cluster of Closely Related Candida tropicalis Genotypes in Italian Patients With Neurological Disorders. |
| Q57900034 | Mycoses and Antifungals: reviewing the basis of a current problem that still is a biotechnological target for marine products |
| Q38589279 | Nosocomial Candidiasis: Antifungal Stewardship and the Importance of Rapid Diagnosis |
| Q41568981 | Novel cutting-edge metabolite-based diagnostic tools for aspergillosis |
| Q26770692 | Potential Use of Phenolic Acids as Anti-Candida Agents: A Review |
| Q33845440 | Purine Acquisition and Synthesis by Human Fungal Pathogens |
| Q38948370 | Revisiting the role of environmental and climate factors on the epidemiology of Kawasaki disease. |
| Q90114163 | SUMOylation in Human Pathogenic Fungi: Role in Physiology and Virulence |
| Q39449899 | Seasonal Distribution of Fungi in Soil Found in Two Hospitals in Bandar Abbas, Iran |
| Q45199703 | Susceptibility Testing of Common and Uncommon Aspergillus Species against Posaconazole and Other Mold-Active Antifungal Azoles Using the Sensititre Method |
| Q28084998 | T2MR and T2Candida: novel technology for the rapid diagnosis of candidemia and invasive candidiasis |
| Q36271354 | The Fungal Mycobiome and Its Interaction with Gut Bacteria in the Host. |
| Q38265845 | Treatment principles for the management of mold infections |
Search more.